Back to search results

Sj-subway, a Predictor for the Recurrence of High-risk Hormone Receptor-positive Breast That is Sensitive to Extended Endocrine Therapy

Abroad (travel likely)Recruiting

Conditions

Breast Cancer

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • Cancer Hospital Affiliated to Harbin Medical University, Harbin, Heilongjiang, China

    Contact: Study coordinator (Xuesong Chen) · cxs1978@163.com · +8615804500816
    Contact: Principal Investigator (Xuesong Chen)

  • The Second Hospital of Jilin University, Changchun, Jilin, China

    Contact: Study coordinator (Yingchao Zhang) · zhang_yc@jlu.edu.cn
    Contact: Principal Investigator (Yingchao Zhang)

  • Dalian Municipal Central Hospital, Dalian, Liaoning, China

    Contact: Study coordinator (Wenbin Guo) · drguowb@hotmail.com · +8613079850586
    Contact: Principal Investigator (Wenbin Guo)

  • Panjin Liaohe Oilfield Gem Flower Hospital, Panjin, Liaoning, China

    Contact: Study coordinator (Hongbin Han) · rose_030201@163.com · +8613704236001
    Contact: Principal Investigator (Hongbin Han)

  • Shengjing Hospital affiliated to China Medical University, Shenyang, Liaoning, China

    Contact: Study coordinator (Nan Niu, MD)
    Contact: Principal Investigator (Cai-Gang Liu, MD)

  • Shengjing Hospital of China Medical University, Shenyang, Liaoning, China

    Contact: Study coordinator (Xi Gu) · jadegx@163.com · +86 18940255116

  • Shengjing Hospital of China Medical University, Shenyang, Liaoning, China

    Contact: Study coordinator (Caigang Liu) · liucg@sj-hospital.org · +86 18940254967
    Contact: Study coordinator (Rong Wu) · wur@sj-hospital.com · +86 18940251156
    Contact: Principal Investigator (Caigang Liu)
    Contact: Principal Investigator (Rong Wu)

  • Shengjing Hospital of China Medical University, Shenyang, Liaoning, China

    Contact: Study coordinator (Nan Niu, MD) · niunannancy@163.com · +8618940256668
    Contact: Principal Investigator (Cai-Gang Liu, MD)

  • The Fourth Affiliated Hospital of China Medical University, Shenyang, Liaoning, China

    Contact: Study coordinator (Wei Tu) · cmu4htw@126.com · +8618900913000
    Contact: Principal Investigator (Wei Tu)

  • Liaoning Cancer Hospital & Institute, Shenyang, Liaoning, China

    Contact: Study coordinator (Hong Xu) · xh4015@163.com · +8618900917779
    Contact: Principal Investigator (Hong Xu)

  • Liaoning Tumor Hospital & Institute, Shenyang, Liaoning, China

    Contact: Study coordinator (Hong Xu) · xh4015@163.com · +86-18900917779

  • People's Hospital of Liaoning Province, Shenyang, Liaoning, China

    Contact: Study coordinator (Qingfeng Liu) · drliuqf1970@126.com · +86-17702486789
Study leads

  • Jin-Qi Xue

    Principal Investigator

    Shengjing Hospital

  • Xi Gu

    Principal Investigator

    Shengjing Hospital

  • Nan Niu

    Principal Investigator

    Shengjing Hospital

  • Tian-Hui Xia

    Principal Investigator

    Shengjing Hospital

  • Wei Tu

    Principal Investigator

    Fourth Affiliated Hospital of China Medical University

  • Hong Xu

    Principal Investigator

    Liaoning Cancer Hospital & Institute

  • Hao Zhang

    Principal Investigator

    Liaoning Cancer Hospital & Institute

  • Yuan-Xi Huang

    Principal Investigator

    Heilongjiang Provicial Hospital

  • Shao-Qiang Cheng

    Principal Investigator

    Heilongjiang Provicial Hospital

  • Bing-Shu Xia

    Principal Investigator

    Heilongjiang Provicial Hospital

  • Wen-Bin Guo

    Principal Investigator

    Dalian Municipal Central Hospital

  • Xue Jiang

    Principal Investigator

    Dalian Municipal Central Hospital

View source on ClinicalTrials.gov(opens in a new tab)